Shield Therapeutics names Jose A. Menoyo as chief medical officer

0
31

Shield Therapeutics PLC (LSE:STX, FRA:1JS) said Jose A. Menoyo, M.D., is joining its senior executive team as vice president and chief medical officer with immediate effect, in a move that is expected to help the launch of its iron deficiency treatment Accrufer in the US.


Dr. Menoyo most recently served as head of US Medical Affairs at rare disease specialist Alexion Pharmaceuticals, Inc., which was acquired by AstraZeneca PLC (LSE:AZN) in July this year. In this role, Menoyo led the Medical Affairs and Health Outcomes and Research teams that supported several launches in the rare disease area.


Prior to joining Alexion, Dr. Menoyo was the senior vice president of Clinical Development and Medical Affairs for ZS Pharma (NASDAQ:ZSPH), which was also eventually acquired by AstraZeneca.


He has also held leadership roles at Amgen, Genzyme (NASDAQ:GENZ) and Sanofi.


Dr. Menoyo completed his Internal Medicine and Nephrology Fellowship at Hahnemann University Hospital and Medical College of Pennsylvania. He will be reporting to Shield chief executive Greg Madison.


Shield is a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer/Feraccru.


WATCH: Shield Therapeutics’ on cusp of US market expansion with focus on commercialising Accrufer


Commenting on the appointment, Madison said: “Dr. Menoyo brings more than 25 years of experience in medical affairs, drug development, and regulatory leadership across both large and small publicly traded biopharmaceutical companies which includes successful drug global launches and commercialisation support.


“Dr. Menoyo has extensive US and global experience in building and leading high performing teams and his particular and proven expertise in establishing and executing Medical Affairs strategies will be extremely valuable to Shield for the launch of Accrufer in the US.”


Shield also confirmed that Tim Watts will resign from the board with effect from 30 September.


“I would like to thank Tim for his crucial role in bringing Shield to the point at which Accrufer can be launched in the US and wish him well for the future,” said Madison.

LEAVE A REPLY

Please enter your comment!
Please enter your name here